Andes Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 19-12-2024
- Paid Up Capital ₹ 0.25 M
as on 19-12-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 35.13%
(FY 2017)
- Profit 274.23%
(FY 2017)
- Ebitda -15.97%
(FY 2017)
- Net Worth 4.05%
(FY 2017)
- Total Assets 15.80%
(FY 2017)
About Andes Laboratories
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.25 M, as per Ministry of Corporate Affairs (MCA) records.
Sachin and Urvesh Mishra serve as directors at the Company.
- CIN/LLPIN
U24232DL2013PTC253448
- Company No.
253448
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jun 2013
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Andes Laboratories Private Limited offer?
Andes Laboratories Private Limited offers a wide range of products and services, including Diabetes Medicine, Pharma Ingredients & Raw Materials, Nervous System and Antipsychotic API, Common Disease Medicines, Steroid, Brain & Nervous System Drugs, Psychotherapeutic Agents, Nutraceuticals & Dietary Supplements, Dietary Supplements, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Andes Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachin  | Director | 03-Jun-2013 | Current |
| Urvesh Mishra | Director | 03-Jun-2013 | Current |
Financial Performance of Andes Laboratories.
Andes Laboratories Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 35.13% increase. The company also saw a substantial improvement in profitability, with a 274.23% increase in profit. The company's net worth moved up by a moderate rise of 4.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Andes Laboratories?
In 2017, Andes Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Andes Laboratories?
Unlock and access historical data on people associated with Andes Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Andes Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Andes Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
